Managing Complications Associated With Increased Longevity in Beta Thalassemia
As the life expectancy for patients with beta thalassemia continues to increase, more and more patients are experiencing age-related complications.
Thalassemias
THALASSEMIAS
FEATURE
LATEST NEWS
Promising New Noninvasive Test Developed for β-Thalassemia in At-Risk Pregnancies
Compared to invasive prenatal diagnosis, a noninvansive assay may be a viable alternative for genotyping a fetus in pregnancy at high-risk for β-thalassemia.
Ferriprox Twice-a-Day Tablet Dosing Approved for Transfusional Iron Overload Due to Thalassemia Syndromes
The FDA has approved a twice-a-day formulation of Ferriprox® (deferiprone; Chiesi) for the treatment of transfusional iron overload due to thalassemia syndromes when current chelation therapy is inadequate.
Altered Bone Marrow Microenvironment Induces Defect of Hematopoietic Stem Cells in β-Thalassemia
For patients with β-thalassemia who undergo HSCT, exposure to a normal microenvironment and the impairment of HSCs may be reversible in the presence of a normal microenvironment and in vivo protein restoration.
Luspatercept Improves Transfusion Burden in Patients with Transfusion-Dependent Beta-Thalassemia
When compared with placebo, luspatercept increased the percentage of patients with transfusion-dependent beta-thalassemia who had a reduction in transfusion burden.
Novel Conditioning Regimen for Haploidentical HSCT in Severe Thalassemia
Both event-free and overall survival at 3 years were 96% for patients with transfusion-dependent thalassemia who underwent transplant.
Mineral and Hormonal Dysfunction Associated With Lower BMD in Thalassemia Major
Hypothyroidism, hyperglycemia, and low adrenocorticotrophic hormone levels are associated with lower bone mass in patients with thalassemia major.
Improving Bone Mass With Iron Chelation Therapy in Transfusion-Dependent Beta Thalassemia
Iron chelation therapy with deferasirox and deferoxamine led to significant improvements in bone mineral density and serum ferritin levels.
As Survival Increases in Beta Thalassemia, Renal Complications Emerge
Renal complications occur in more than half of patients with beta thalassemia, but research on their epidemiology and treatment is limited.
Utility of Flow Cytometry to Detect Red Blood Cell Alloimmunization in Thalassemia
Red blood cell alloantibodies were detected more than 4 times as frequently with flow cytometry compared with direct Coombs test.
Reducing Transfusion Burden and Addressing Unmet Needs in Beta Thalassemia
Lack of resources and poor awareness of thalassemia can make it difficult for patients with beta thalassemia to receive necessary blood transfusions.
White Matter Changes and Headache in Thalassemia
Recurrent headache was reported by 61% of patients with thalassemia compared with 22.5% of healthy individuals in a control arm.
The Efficacy of Intrabone Gene Therapy for Transfusion-Dependent Beta Thalassemia
Allogeneic HSC gene therapy may be an alternative to transplantation for patients with transfusion-dependent thalassemia.
Luspatercept May Improve Hemoglobin Levels in Patients With Beta Thalassemia
A high percentage of patients with beta thalassemia demonstrated an increase in hemoglobin levels after receiving luspatercept.
New Iron Chelator May Improve Cardiac Function in Patients With Beta Thalassemia
A new oral iron chelator, deferasirox, may confer long-term benefits to patients with beta thalassemia major.
A Novel Health-Related Quality of Life Assessment Tool for Nontransfusion-Dependent Beta Thalassemia
Modern tools for measuring health-related quality of life may not capture symptoms unique to patients with nontransfusion-dependent thalassemia.
Managing Atrial Fibrillation in Patients With Beta Thalassemia Major
Patients with beta thalassemia major may be at higher risk for atrial fibrillation, creating a need for attentive clinical management.
Peripheral Blood: An Alternative Source of Stem Cells in Thalassemia
Accessing peripheral blood as a graft source is easier and less invasive than accessing bone marrow.
Serum Ferritin May Unreliably Predict Iron Overload in Patients with Thalassemia Major
Iron overload that persists after HSCT can cause long-term organ damage.
Managing Medical Complications of Beta-Thalassemia in Adults: An Experience-Based Perspective
Mortality in beta-thalassemia has decreased due to medical advances, allowing physicians to observe and manage disease-related complications in adult patients.
Want to read more?
Please login or register first to view this content.
